264 related articles for article (PubMed ID: 32336953)
1. Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies.
Kaur A; Goggolidou P
J Inflamm (Lond); 2020; 17():15. PubMed ID: 32336953
[TBL] [Abstract][Full Text] [Related]
2. Genetic heterogeneity within ulcerative colitis determined by an interleukin-1 receptor antagonist gene polymorphism and antineutrophil cytoplasmic antibodies.
Papo M; Quer JC; Gutierrez C; Broch M; Casellas F; Pastor RM; Olona M; Richart C
Eur J Gastroenterol Hepatol; 1999 Apr; 11(4):413-20. PubMed ID: 10321759
[TBL] [Abstract][Full Text] [Related]
3. KFL2 participates in the development of ulcerative colitis through inhibiting inflammation via regulating cytokines.
Wang ZL; Wang YD; Wang K; Li JA; Li L
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4941-4948. PubMed ID: 30070340
[TBL] [Abstract][Full Text] [Related]
4. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
5. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
6. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.
Reinecker HC; Steffen M; Witthoeft T; Pflueger I; Schreiber S; MacDermott RP; Raedler A
Clin Exp Immunol; 1993 Oct; 94(1):174-81. PubMed ID: 8403503
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.
Baird AC; Mallon D; Radford-Smith G; Boyer J; Piche T; Prescott SL; Lawrance IC; Tulic MK
World J Gastroenterol; 2016 Nov; 22(41):9104-9116. PubMed ID: 27895398
[TBL] [Abstract][Full Text] [Related]
8. The role of the Notch signalling pathway in the pathogenesis of ulcerative colitis: from the perspective of intestinal mucosal barrier.
Ning H; Liu J; Tan J; Yi M; Lin X
Front Med (Lausanne); 2023; 10():1333531. PubMed ID: 38249980
[TBL] [Abstract][Full Text] [Related]
9. Mucosal CXCR4+ IgG plasma cells contribute to the pathogenesis of human ulcerative colitis through FcγR-mediated CD14 macrophage activation.
Uo M; Hisamatsu T; Miyoshi J; Kaito D; Yoneno K; Kitazume MT; Mori M; Sugita A; Koganei K; Matsuoka K; Kanai T; Hibi T
Gut; 2013 Dec; 62(12):1734-44. PubMed ID: 23013725
[TBL] [Abstract][Full Text] [Related]
10. Moxibustion treatment modulates the gut microbiota and immune function in a dextran sulphate sodium-induced colitis rat model.
Qi Q; Liu YN; Jin XM; Zhang LS; Wang C; Bao CH; Liu HR; Wu HG; Wang XM
World J Gastroenterol; 2018 Jul; 24(28):3130-3144. PubMed ID: 30065559
[TBL] [Abstract][Full Text] [Related]
11. First case report of exacerbated ulcerative colitis after anti-interleukin-6R salvage therapy.
Atreya R; Billmeier U; Rath T; Mudter J; Vieth M; Neumann H; Neurath MF
World J Gastroenterol; 2015 Dec; 21(45):12963-9. PubMed ID: 26668517
[TBL] [Abstract][Full Text] [Related]
12. Mend Your Fences: The Epithelial Barrier and its Relationship With Mucosal Immunity in Inflammatory Bowel Disease.
Martini E; Krug SM; Siegmund B; Neurath MF; Becker C
Cell Mol Gastroenterol Hepatol; 2017 Jul; 4(1):33-46. PubMed ID: 28560287
[TBL] [Abstract][Full Text] [Related]
13. Alterations of the mucosal immune system in inflammatory bowel disease.
MacDermott RP
J Gastroenterol; 1996 Dec; 31(6):907-16. PubMed ID: 9027661
[TBL] [Abstract][Full Text] [Related]
14. Inflammation and Inflammatory Cytokine Contribute to the Initiation and Development of Ulcerative Colitis and Its Associated Cancer.
Yao D; Dong M; Dai C; Wu S
Inflamm Bowel Dis; 2019 Sep; 25(10):1595-1602. PubMed ID: 31287863
[TBL] [Abstract][Full Text] [Related]
15. Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease-Focusing on Intestinal Barrier Function.
Schoultz I; Keita ÅV
Cells; 2019 Feb; 8(2):. PubMed ID: 30813280
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil Extracellular Traps Sustain Inflammatory Signals in Ulcerative Colitis.
Dinallo V; Marafini I; Di Fusco D; Laudisi F; Franzè E; Di Grazia A; Figliuzzi MM; Caprioli F; Stolfi C; Monteleone I; Monteleone G
J Crohns Colitis; 2019 May; 13(6):772-784. PubMed ID: 30715224
[TBL] [Abstract][Full Text] [Related]
17. Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease).
Ruther U; Nunnensiek C; Muller HA; Bader H; May U; Jipp P
Hepatogastroenterology; 1998; 45(21):691-9. PubMed ID: 9684118
[TBL] [Abstract][Full Text] [Related]
18. Sphingolipids in neutrophil function and inflammatory responses: Mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis.
Espaillat MP; Kew RR; Obeid LM
Adv Biol Regul; 2017 Jan; 63():140-155. PubMed ID: 27866974
[TBL] [Abstract][Full Text] [Related]
19. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.
Sartor RB
Gastroenterol Clin North Am; 1995 Sep; 24(3):475-507. PubMed ID: 8809232
[TBL] [Abstract][Full Text] [Related]
20. Experimental immunomodulatory therapy of inflammatory bowel disease.
Schreiber S
Neth J Med; 1998 Dec; 53(6):S24-31. PubMed ID: 9883011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
